In a new filing with the Securities and Exchange Commission, James E. Flynn of Deerfield Management, has revealed a 6.05% stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Deerfield’s passive position amasses 1.42 million shares of the company, up from some 565,200 shares held as of the end of the first quarter of the year.
Among other investors that own shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) as of the end of March is Baker Bros. Advisors, led by Julian Baker and Felix Baker, which held almost 299,400 shares, according to their latest 13F filing. Joseph Edelman‘s Perceptive Advisors has reduced its exposure to the company by 30% during the first three months of the year, to 211,500 shares. On the other hand, Stuart Weisbrod‘s Iguana Healthcare Management has upped its stake by 87% to 210,000 shares.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) is a small cap clinical-stage pharmaceutical company, which is specialized on products for therapy for the treatment of glaucoma and other eye diseases.